Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a pilot study to identify biomarkers that individually, and in combination, demonstrate the greatest sensitivity to repetitive, low-level blast exposure (RLLBE) neurotrauma in Special Operations Forces (SOF) personnel. The proposed cross-sectional, multimodal study will elucidate the potential effects of long-term RLLBE by comparing biomarkers across subjects.
The proposal includes a comprehensive battery of assessments characterized by high-field neuroimaging, proteomics, and experimental cognitive and neurobehavioral evaluations, which will be implemented alongside standardized clinical diagnostic tools. The results will inform the design of a larger trial to validate the diagnostic utility of these biomarkers as well as their ability to predict RLLBE-related clinical outcomes. A secondary aim will be to define the underlying mechanisms, risk and resilience factors, and clinical phenotypes associated with RLLBE.
Biomarkers assessed over the course of a two-day evaluation will include:
We hypothesize that a multimodal assessment using Connectome MRI, 7 Tesla MRI, TSPO PET, Tau PET, cognitive/behavioral tests, proteomics and metabolomics will identify biomarkers of RLLBE-related brain injury.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Special Operations Forces (SOF) Personnel | n=30 SOF Personnel |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 3T Connectome MRI | Diagnostic Test | MRI scan of structural connectivity |
|
| Measure | Description | Time Frame |
|---|---|---|
| Diffusion MRI structural connectivity | measured by white matter tractography | Day 1 |
| fMRI resting state functional connectivity | measured by default mode network connectivity | Day 2 |
| PET Neuroinflammation | measured by standardized uptake value ratio of TSPO ligand [11C]PBR28 | Day 1 |
| PET Tau deposition | measured by standardized uptake value ratio of [18F]MK6240 | Day 2 |
| Neurofilament Light Chain | measured by serum concentration of neurofilament light chain | Day 1, after 6-8 hour fasting |
| Cognitive Function | measured by the Trail Making Test | Day 1 |
| Behavioral symptoms | measured by the Neurobehavioral Symptom Inventory | Day 2 |
| Physical symptoms | measured by the Neurobehavioral Symptom Inventory | Day 2 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
History of moderate or severe traumatic brain injury (TBI) (using the VA/DOD definition: initial Glasgow Coma Scale score < 13, coma duration > ½ hr, post-traumatic amnesia duration > 24 hr, or abnormal structural brain imaging)
History of major neurologic disorder such as stroke or spinal cord injury resulting in a significant decrement in functional status or loss of independent living capacity
Untreated or unstable severe psychiatric condition (e.g., schizophrenia or bipolar disorder) that is likely to impact study participation or ability to complete study procedures
Current severe medical condition (excluding currently diagnosed mild TBI or concussion) that requires long-term treatments (e.g., cancer, diabetes mellitus, human immunodeficiency virus, autoimmune disorders)
Any cardiac, respiratory, or other medical condition that may affect cerebral metabolism
Benzodiazepines other than lorazepam, desmethyldiazepam and oxazepam within past month
MRI contraindications
Prior radiation exposure of ≥ 50 mSv over the past 12 months, in the context of research, as determined by review of DOD medical records (e.g., prior imaging studies) and self-report
Any condition which, in the opinion of the Principal Investigator, may cause undue risk to the subject
Other: Any condition or characteristic that in the judgment of the Principal Investigator would create a logistical or safety contraindication to enrollment (e.g., shoulder width greater than the bore of the MRI or PET/MRI machines)
Males, regardless of race or ethnicity, currently serving in the Special Operation Forces
U.S. Special Operations Forces personnel
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Brian L Edlow, M.D. | Massachusetts General Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Jul 23, 2025 | |
| Reset | Aug 7, 2025 |
Not provided
Not provided
Not provided
Not provided
| 7 Tesla MRI | Diagnostic Test | MRI scan of functional connectivity |
|
| TSPO PET | Diagnostic Test | PET scan of neuroinflammation |
|
| Tau PET | Diagnostic Test | PET scan of tau deposition |
|
| Cognitive and Behavioral Assessments | Diagnostic Test | Assessments of memory, attention, complex reasoning, mood and other cognitive/behavioral domains |
|
| Blood Biomarkers | Diagnostic Test | Blood-based assessments of proteomic and metabolic biomarkers of brain injury |
|
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jul 23, 2025 | Aug 7, 2025 |
| ID | Term |
|---|---|
| D000070642 | Brain Injuries, Traumatic |
| D001753 | Blast Injuries |
| ID | Term |
|---|---|
| D001930 | Brain Injuries |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D006259 | Craniocerebral Trauma |
| D020196 | Trauma, Nervous System |
| D014947 | Wounds and Injuries |
| D001469 | Barotrauma |
Not provided
Not provided